FrancophonIA/ELRC3.0 huggingface dataset:
English: The doctor will ensure that the risks linked to the radioactive exposure are lower than the risks from the disease itself.
Slovenian: Zdravnik se mora prepričati, da so tveganja, povezana z radioaktivnim izpostavljanjem, manjša od tveganj, povezanih s samo boleznijo.
English: What benefit has Yttriga shown during the studies?
Slovenian: Kakšne koristi je zdravilo Yttriga izkazalo med študijami?
English: This is a summary of the European public assessment report (EPAR) for Yttriga.
Slovenian: Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Yttriga.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Yttriga on 19 January 2006.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Yttriga, veljavno po vsej Evropski uniji, odobrila dne19.
English: What is the risk associated with Yttriga?
Slovenian: Kakšna tveganja so povezana z zdravilom Yttriga?
English: The company also presented published information on the effect of using 90Y to radiolabel other medicines, including one study of non-Hodgkin's lymphoma (a cancer of the lymph tissue, part of the immune system).
Slovenian: Predstavila je tudi že objavljene podatke o učinku uporabe 90Y za radioaktivno označevanje drugih zdravil, vključno s študijo ne-Hodgkinovega limfoma (raka limfnega tkiva, ki je del imunskega sistema).
English: Radiolabelling of a medicine takes place outside the body in a laboratory setting.
Slovenian: Radioaktivno označevanje zdravila poteka zunaj telesa v laboratoriju.
English: Yttriga must not be given directly to any patient.
Slovenian: Zdravilo Yttriga se nobenemu bolniku ne sme dati neposredno.
English: Yttriga is never given directly to a patient.
Slovenian: Zdravilo Yttriga se nikoli ne da neposredno bolniku.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Yttriga.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Yttriga, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Once the substance is labelled with Yttriga, it then carries the radioactivity to where it is needed in the body, for example the site of a tumour.
Slovenian: Ko je snov označena z zdravilom Yttriga, prenese radioaktivnost na mesto, kjer je v telesu potrebna, na primer tja, kjer se tumor nahaja.
English: As Yttriga will only be used to prepare radiolabelled medicines, no studies of Yttriga have been done in humans.
Slovenian: Ker bo zdravilo Yttriga uporabljeno le za pripravo radioaktivno označenih zdravil, študije pri ljudeh niso bile izvedene.
English: The radiolabelled medicine is then given to the patient according to the instructions in that medicine's summary of product characteristics (SmPC).
Slovenian: Radioaktivno označeno zdravilo se nato da bolniku v skladu z navodili iz povzetka glavnih značilnosti (SmPC) za to zdravilo.
English: Yttriga is only to be used by specialists who have experience in radiolabelling.
Slovenian: Zdravilo Yttriga smejo uporabljati samo specialisti, ki imajo izkušnje na področju radioaktivnega označevanja.
English: The information supplied by the company shows the utility of Yttriga as a precursor to radiolabel medicines with 90Y.
Slovenian: Podatki, ki jih je predložila družba, kažejo koristnost zdravila Yttriga kot predhodnika za radioaktivno označevanje zdravil z 90Y.
English: Why has Yttriga been approved?
Slovenian: Zakaj je bil zdravilo Yttriga odobreno?
English: The CHMP decided that Yttriga's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Yttriga večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
English: Medicines radiolabelled with Yttriga should not be used in people who may be hypersensitive (allergic) to yttrium chloride or any of the other ingredients.
Slovenian: Zdravil, ki so radioaktivno označena z zdravilom Yttriga, ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) itrijev klorid ali katero koli drugo sestavino zdravila.
English: Yttriga is used to label medicines that have been specially developed for use with yttrium (90Y) chloride.
Slovenian: Zdravilo Yttriga se uporablja za označevanje zdravil, ki so bila posebej razvita za uporabo z itrijevim (90Y) kloridom.
English: The side effects seen with treatment involving Yttriga will therefore depend largely on the medicine being labelled and will be described in that medicine's package leaflet.
Slovenian: Neželeni učinki, opaženi pri zdravljenju z zdravilom Yttriga, so zato odvisni predvsem od označenega zdravila in so opisani v navodilu za uporabo tega zdravila.
English: Yttriga is a precursor and will not be given on its own.
Slovenian: Zdravilo Yttriga je predhodnik in se ne uporablja kot samostojno zdravilo.
English: The active substance in Yttriga, yttrium (90Y) chloride, is a radioactive compound that emits a type of radiation known as beta radiation.
Slovenian: Zdravilna učinkovina zdravila Yttriga, itrijev (90Y) klorid, je radioaktivna spojina, ki oddaja vrsto radioaktivnega sevanja, znano kot beta sevanje.
English: Radiolabelling is a technique where a substance is labelled (tagged) with a radioactive compound.
Slovenian: Radioaktivno označevanje je tehnika, pri kateri se snov označi z radioaktivno snovjo.
English: 90Y, or yttrium-90, is a radioactive form of the chemical element yttrium.
Slovenian: 90Y ali itrij90 je radioaktivna oblika kemijskega elementa itrija.
English: Yttriga is not used on its own but is used for radiolabelling other medicines.
Slovenian: Zdravilo Yttriga se ne uporablja kot samostojno zdravilo, ampak za radioaktivno označevanje drugih zdravil.
English: More information on the restrictions on the use of medicines radiolabelled with Yttriga will be found in their package leaflets.
Slovenian: Za več informacij o omejitvah glede uporabe zdravil, ki so radioaktivno označena z zdravilom Yttriga, glejte navodila za uporabo teh zdravil.
English: Yttriga itself is radioactive and so its use in radiolabelling may carry a risk of cancer and hereditary defects.
Slovenian: Zdravilo Yttriga je radioaktivno, zato je njegova uporaba pri radioaktivnem označevanju lahko povezana s tveganjem za pojav rakavega obolenja ali razvoj prirojenih okvar.
English: What is Yttriga used for?
Slovenian: Za kaj se zdravilo Yttriga uporablja?
English: The effect of Yttriga depends on the nature of the medicine that is radiolabelled with it. An example of its use is the treatment of some type of tumours, where the radiolabelled medicine carries the radioactivity to the site of a tumour to destroy the tumour cells.
Slovenian: Primer njegove uporabe predstavlja zdravljenje nekaterih vrst tumorjev, pri čemer radioaktivno označeno zdravilo prenese radioaktivnost na mesto, kjer se tumor nahaja, da uniči tumorske celice.
English: Yttriga is a radioactive liquid that contains the active substance yttrium (90Y) chloride.
Slovenian: Zdravilo Yttriga je radioaktivna tekočina, ki vsebuje zdravilno učinkovino itrijev (90Y) klorid.
English: Yttriga yttrium (90Y) chloride
Slovenian: Y) klorid
English: How has Yttriga been studied?
Slovenian: Kako je bilo zdravilo Yttriga raziskano?
English: What is Yttriga?
Slovenian: Kaj je zdravilo Yttriga?
English: How is Yttriga used?
Slovenian: Kako se zdravilo Yttriga uporablja?
English: How does Yttriga work?
Slovenian: Kako zdravilo Yttriga deluje?
English: See instructions below.
Slovenian: Glejte spodnja navodila.
English: Your doctor will not prescribe PROTELOS for you if you are at particular risk.
Slovenian: Zdravnik vam ne bo predpisal zdravila PROTELOS, če pri vas obstaja posebno tveganje.
English: Anpharm Przedsiebiorstwo Farmaceutyczne S.A. 03-236 Warszawa ul.
Slovenian: Anpharm Przedsiebiorstwo Farmaceutyczne S.A. 03-236 Varšava ul.
English: You can take PROTELOS again when you have finished taking these antibiotics.
Slovenian: Zdravilo PROTELOS lahko ponovno začnete jemati, ko prenehate z jemanjem tovrstnih antibiotikov.
English: PROTELOS with food and drink:
Slovenian: Zdravilo PROTELOS skupaj s hrano in pijačo:
English: Other medicines and PROTELOS:
Slovenian: Druga zdravila in zdravilo PROTELOS:
English: If tests are positive for one or both alleles, PROTELOS should not be started.
Slovenian: Če so testi pozitivni za enega ali oba alela, se zdravila PROTELOS ne sme uvesti.
English: What PROTELOS is and what it is used for
Slovenian: Kaj je zdravilo PROTELOS in za kaj ga uporabljamo
English: - if you have severe kidney disease.
Slovenian: - če imate hudo bolezen ledvic.
English: What PROTELOS is and what it is used for What you need to know before you take PROTELOS How to take PROTELOS
Slovenian: Kaj je zdravilo PROTELOS in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo PROTELOS Kako jemati zdravilo PROTELOS
English: Adverse reactionsare listed below using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Slovenian: Neželeni učinki so našteti po naslednjem pravilu: zelo pogosti (≥ 1/10), pogosti (≥1/100 do <1/10, občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000) zelo redki (< 1/10.000); neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
English: PROTELOS has been studied in clinical trials involving nearly 8,000 participants.
Slovenian: Zdravilo PROTELOS so proučevali v kliničnih študijah, ki so zajele skoraj 8000 bolnikov.
English: Your doctor will tell you how long you should continue to take PROTELOS.
Slovenian: Zdravnik vam bo povedal, koliko časa morate jemati zdravilo PROTELOS.
English: INFORMATION IN BRAILLE PROTELOS 2 g
Slovenian: PODATKI V BRAILLOVI PISAVI PROTELOS 2 g
English: If you have stopped treatment due to hypersensitivity reactions, do not take PROTELOS again.
Slovenian: Če ste prenehali z zdravljenjem zaradi preobčutljivostnih reakcij, zdravila PROTELOS ne jemljite več.
English: PROTELOS should not be used during breast-feeding.
Slovenian: PROTELOS se ne sme uporabljati med dojenjem.
English: • The contraindications to the treatment with PROTELOS.
Slovenian: • kontraindikacije za zdravljenje z zdravilom PROTELOS,
English: Your doctor should be able to advise if a blood test is necessary before taking PROTELOS.
Slovenian: Vaš zdravnik vam bo svetoval, ali je potrebno izvesti krvni test, preden začnete jemati zdravilo PROTELOS.
English: Children and adolescents PROTELOS is not intended for use in children and adolescents (below the age of 18).
Slovenian: Zdravilo PROTELOS ni namenjeno otrokom in mladostnikom (mlajšim od 18 let).
English: If you need to have blood or urine tests to check your level of calcium, you should tell the laboratory that you are taking PROTELOS as it may interfere with some testing methods.
Slovenian: Če morate opraviti preiskave krvi ali urina, ki pokažejo vašo raven kalcija, morate osebju v laboratoriju povedati, da jemljete zdravilo PROTELOS, ker lahko jemanje zdravila vpliva na nekatere laboratorijske preiskave.
English: It is recommended that you take PROTELOS in-between meals, preferably at bedtime at least two hours after food, milk or milk products or calcium supplements.
Slovenian: Priporočljivo je, da PROTELOS jemljete v času med dvema obrokoma, najbolje pred spanjem, najmanj dve uri po zaužitju hrane, mleka ali mlečnih izdelkov in dodatkov kalcija.
English: If you take more PROTELOS than you should:
Slovenian: Če ste vzeli večji odmerek zdravila PROTELOS, kot bi smeli:
English: The safety and efficacy of PROTELOS in children aged below 18 years have not been established.
Slovenian: Pediatrična populacija Varnost in učinkovitost zdravila PROTELOS pri otrocih, mlajših od 18 let, nista bili dokazani.
English: • The initiation of treatment with PROTELOS should be based on an assessment of the individual patient's overall risk.
Slovenian: • Odločitev o uvedbi zdravljenja z zdravilom PROTELOS mora temeljiti na podlagi ocene skupnega tveganja za posameznega bolnika.
English: Musculo-skeletal fraction > 3 times the upper limit of the normal range.
Slovenian: a Mišičnoskeletna frakcija > 3-kratna gornja meja razpona normalnih vrednosti.
English: Pharmacokinetics in special populations
Slovenian: Farmakokinetika pri posebnih skupinah Starejši
English: You may lie down immediately after taking PROTELOS if you wish.
Slovenian: Če želite, se lahko uležete takoj po jemanju zdravila PROTELOS.
English: When treating patients over 80 years at risk of VTE, the need for continued treatment with PROTELOS should be re-evaluated.
Slovenian: Pri zdravljenju bolnikov, starejših od 80 let s tveganjem za vensko trombembolijo, moramo potrebo po nadaljnjem zdravljenju z zdravilom PROTELOS ponovno ovrednotiti.
English: Your doctor will evaluate the conditions of your heart and blood vessels regularly, generally every 6 to 12 months for as long you are taking PROTELOS.
Slovenian: Vaš zdravnik bo redno, vsakih 6 do 12 mesecev, ocenil stanje vašega srca in krvnih žil, vse dokler boste jemali zdravilo PROTELOS.
English: However, when this dosing regimen is impractical due to the recommended administration of PROTELOS at bedtime, concomitant intake remains acceptable.
Slovenian: Kadar pa tovrsten režim odmerjanja ni praktičen zaradi priporočenega jemanja zdravila PROTELOS pred spanjem, sočasno jemanje ostaja sprejemljivo.
English: If you forget to take PROTELOS:
Slovenian: Če ste pozabili vzeti zdravilo PROTELOS:
English: - if you are immobilised permanently or for some time such as being wheel-chair bound, or confined to bed or if you are to undergo an operation or recovering from an operation.
Slovenian: - če ste trajno ali nekaj časa nepokretni, npr. ste vezani na invalidski voziček ali na posteljo, če čakate na operacijo ali po njej okrevate.
English: Mean age was 75 years at inclusion and 23% of the patients enrolled were 80 to 100 years of age.
Slovenian: Srednja starost ob vključitvi je bila 75 let in 23 % vključenih bolnic je bilo starih od
English: The risk of vein thrombosis (blood clots in the leg or lungs) may be increased in the event of lengthy immobilisation.
Slovenian: Tveganje venske tromboze (krvni strdki v nogah ali v pljučih) se lahko poveča, če ste dlje časa nepokretni;
English: Available data indicate that these factors account for approximately 50% of the measured change in BMD over 3 years of treatment with PROTELOS 2 g/day.
Slovenian: Dostopni podatki kažejo, da ta dejavnika povzročata približno 50 % izmerjene spremembe mineralne kostne gostote v 3 letih zdravljenja z zdravilom PROTELOS po 2 g na dan.
English: and TROPOS enrolled 1,556 patients over 80 years at inclusion (23.1% of the study population).
Slovenian: Skupaj sta študiji SOTI in TROPOS zajeli 1556 bolnic, ki so bile ob vključitvi starejše od 80 let (23,1 % proučevane populacije).
English: PROTELOS can treat your severe osteoporosis only if you continue to take it.
Slovenian: Zdravilo PROTELOS lahko zdravi hudo osteoporozo, le če ga jemljete neprekinjeno.
English: In each Member State where PROTELOS is marketed, the Marketing Authorisation Holder (MAH) shall agree the final educational programme with the National Competent Authority.
Slovenian: Dodatni ukrepi za zmanjševanje tveganja V posamezni državi članici, kjer se zdravilo PROTELOS trži, se mora imetnik dovoljenja za promet z zdravilom (MAH) dogovoriti s pristojnim nacionalnim organom o končnem izobraževalnem programu.
English: simultaneous administration of strontium ranelate with these medicinal products is not recommended.
Slovenian: sočasno jemanje stroncijevega ranelata s tovrstnimi zdravili ni priporočeno.
English: PROTELOS can interact with milk and milk products, so it is important that you mix PROTELOS only with water to be sure it works properly.
Slovenian: Zdravilo PROTELOS lahko medsebojno deluje z mlekom in mlečnimi izdelki, zato je za pravilno delovanje pomembno, da zdravilo PROTELOS mešate le z vodo.
English: It is important that you continue taking PROTELOS for as long as your doctor prescribes the medicine.
Slovenian: Pomembno je, da z jemanjem zdravila PROTELOS nadaljujete tako dolgo, kot vam je predpisal zdravnik.
English: PROTELOS contains aspartame, a source of phenylalanine, which may be harmful for people with phenylketonuria.
Slovenian: Zdravilo PROTELOS vsebuje aspartam, vir fenilalanina, ki je lahko škodljiv za bolnike s fenilketonurijo.
English: - if you have or have had a blood clot (for example, in the blood vessels in your legs or lungs).
Slovenian: - če imate ali ste imeli krvni strdek (npr. v žilah v nogah ali v pljučih);
English: Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Slovenian: Znanstveni zaključki in podlaga za spremembo pogojev dovoljenj za promet z zdravilom
English: You should stop taking PROTELOS if you have to take oral tetracyclines such as doxycycline or quinolones such as ciprofloxacin (two types of antibiotics).
Slovenian: Prenehajte jemati zdravilo PROTELOS, če se zdravite s peroralnimi tetraciklini, kot je npr. doksiciklin ali kinoloni, kot je npr. ciprofloksacin (dve vrsti antibiotikov).
English: In phase III studies, which demonstrated the anti-fracture efficacy of PROTELOS treatment, measured mean BMD increased from baseline with PROTELOS by approximately 4% per year at the lumbar spine and 2% per year at the femoral neck, reaching 13% to 15% and 5% to 6% respectively after 3 years, depending on the study.
Slovenian: V študijah III. faze, ki so dokazovale učinkovitost zdravila PROTELOS pri preprečevanju zlomov, se je izmerjena srednja mineralna kostna gostota ob zdravilu PROTELOS povečevala od izhodišča za približno 4 % na leto v ledveni hrbtenici in 2 % na leto v vratu stegnenice, vrednosti pa so dosegle 13 do 15 % oziroma 5 do 6 % po 3 letih, odvisno od študije.
English: PROTELOS is a medicine used to treat severe osteoporosis: - in postmenopausal women, - in adult men, at high risk of fracture, for whom other alternative treatments are not possible.
Slovenian: PROTELOS je zdravilo za zdravljenje hude osteoporoze: - pri ženskah po menopavzi, - pri odraslih moških, z visokim tveganjem za zlome, pri katerih druga alternativna zdravljenja niso mogoča.
English: Strontium ranelate is made up of 2 atoms of stable strontium and 1 molecule of ranelic acid, the organic part permitting the best compromise in terms of molecular weight, pharmacokinetics and acceptability of the medicinal product.
Slovenian: 5.2 Farmakokinetične lastnosti Stroncijev ranelat sestavljata 2 atoma stabilnega stroncija in 1 molekula ranelske kisline, organskega dela, ki omogoča najboljši kompromis glede na molekulsko maso, farmakokinetiko in prenašanje zdravila.
English: If you take more sachets of PROTELOS than recommended by your doctor, tell your doctor or pharmacist.
Slovenian: Če ste vzeli več vrečk zdravila PROTELOS, kot vam jih je priporočil vaš zdravnik, obvestite svojega zdravnika ali farmacevta.
English: Manufacturer(s) Les Laboratoires Servier Industrie 905, route de Saran 45520 Gidy
Slovenian: Les Laboratoires Servier Industrie 905, route de Saran 45520 Gidy
English: Table 1: Incidence of patients with vertebral fracture and relative risk reduction
Slovenian: Preglednica 1: Pojavnost zlomov vretenc pri bolnicah in zmanjšanje relativnega tveganja
English: If you stop taking PROTELOS:
Slovenian: Če prenehate jemati zdravilo PROTELOS:
English: On the basis of the scientific conclusions for the results of the study for the medicinal product mentioned above, the CHMP is of the opinion that the benefit-risk balance of this medicinal product is unchanged, subject to the proposed changes to the product information.
Slovenian: Podlaga za spremembe pogojev dovoljenja za promet z zdravilom Na podlagi znanstvenih zaključkov o izsledkih študije z zgoraj navedenim zdravilom odbor CHMP meni, da je razmerje med koristjo in tveganjem tega zdravila nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
English: PROTELOS is supplied in boxes of 7, 14, 28, 56, 84 or 100 sachets.
Slovenian: Škatle zdravila PROTELOS vsebujejo 7, 14, 28, 56, 84 ali 100 vrečk.
English: If PROTELOS is used inadvertently during pregnancy, treatment must be stopped.
Slovenian: Če bolnica nehote jemlje zdravilo PROTELOS med nosečnostjo, mora jemanje prekiniti.
English: As divalent cations can form complexes with oral tetracycline (e.g. doxycycline) and quinolone antibiotics (e.g. ciprofloxacin) at the gastro-intestinal level and thereby reduce their absorption,
Slovenian: Ker dvovalentni kationi lahko tvorijo kompleks s peroralnimi tetraciklini (npr. doksiciklinom) in kinolonskimi antibiotiki (npr. ciprofloksacinom) v prebavilih in tako zmanjšujejo njihovo absorpcijo,
English: How to take PROTELOS
Slovenian: Kako jemati zdravilo PROTELOS
English: PROTELOS also decreased the number of patients with a body height loss of at least 1 cm as compared to placebo.
Slovenian: Zdravilo PROTELOS je v primerjavi s placebom zmanjšal tudi število bolnic z izgubo telesne višine za najmanj 1 cm.
English: If you are taking medicines containing calcium, you should leave at least 2 hours before you take PROTELOS.
Slovenian: Če jemljete zdravila, ki vsebujejo kalcij, je priporočljivo počakati najmanj 2 uri, preden boste vzeli zdravilo PROTELOS.
English: Over 12 months, a statistically significant increase in mean lumbar spine BMD, main efficacy criteria (E (SE) = 5.32% (0.75); 95%CI = [3.86 ; 6.79]; p<0,001), similar to that observed in the pivotal antifracture phase III studies carried-out inpostmenopausal women, was observed.
Slovenian: Po 12 mesecih so opažali statistično značilna povečanja srednje mineralne kostne gostote v ledveni hrbtenici, glavni kriterij učinkovitosti (E (SE) = 5,32 % (0,75); 95 % IZ = [3.86; 6.79); p < 0,001), podobno kot v temeljnih študijah III. faze, ki so dokazovale učinkovitost preprečevanja zlomov pri ženskah po menopavzi.
English: The highest risk for occurrence of SJS or TEN is within the first weeks of treatment and usually around 3-6 weeks for DRESS.
Slovenian: Največje tveganje za pojav SJS ali TEN je v prvih tednih zdravljenja, za pojav sindroma DRESS pa običajno okoli 3 do 6 tednov od uvedbe zdravljenja.
English: As a precautionary measure, PROTELOS treatment should be suspended during treatment with oral tetracycline or quinolone antibiotics.
Slovenian: Kot previdnostni ukrep je treba med zdravljenjem s peroralnimi tetraciklini ali kinolonskimi antibiotiki jemanje zdravila PROTELOS prekiniti.
English: During treatment, if you experience an allergic reaction (such as swelling of the face, tongue or throat, difficulty in breathing or swallowing, skin rash), you must immediately stop taking PROTELOS and seek medical advice (see section 4).
Slovenian: Če med zdravljenjem doživite hude alergijske reakcije (kot so zatekanje obraza, jezika ali grla, težave pri dihanju ali požiranju, kožni izpuščaj), morate nemudoma prenehati z jemanjem zdravila PROTELOS in poiskati zdravniško pomoč (glejte poglavje 4).
English: Do not take PROTELOS during pregnancy or when you are breastfeeding.
Slovenian: Zdravila PROTELOS ne smete jemati med nosečnostjo ali če dojite.
English: In a pooled analysis of randomised placebo-controlled studies in post-menopausal osteoporotic patients , the most common adverse reactions consisted of nausea and diarrhoea, which were generally reported at the beginning of treatment with no noticeable difference between groups afterwards.
Slovenian: V združeni analizi randomiziranih, s placebom nadzorovanih raziskav pri bolnicah z osteoporozo po menopavzi, sta bila najpogostejša neželena učinka slabost in diareja, ki so ju večinoma opažali na začetku zdravljenja, kasneje pa ni bilo opaznih razlik med skupinama.